C-reactive protein may be a prognostic factor in hepatocellular carcinoma with malignant portal vein invasion

World Journal of Surgical Oncology

Volumn 11, Issue , 2013, Pages

  Kim, Jong M ^a   Kwon, Choon Hyuck D ^a   Joh, Jae Won ^a   Ko, Justin S ^a   Park, Jae B ^a   Lee, Joon H ^a   Kim, Sung J ^a   Paik, Seung W ^a   Park, Cheol Keun ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

C reactive protein; Hepatectomy; Hepatocellular carcinoma; Malignant portal vein invasion; Tumor recurrence

Indexed keywords

ALKALINE PHOSPHATASE; C REACTIVE PROTEIN;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT PORTAL VEIN INVASION; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TUMOR INVASION; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PORTAL VEIN; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84876723146     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-11-92     Document Type: Article

References (22)

1. Song IH, Kim KS. Current status of liver diseases in Korea: hepatocellular carcinoma. Korean J Hepatol 2009, Suppl 6:S50-S59.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917. 10.1016/S0140-6736(03)14964-1, 14667750.
3. Matsumata T, Kanematsu T, Takenaka K, Yoshida Y, Nishizaki T, Sugimachi K. Patterns of intrahepatic recurrence after curative resection of hepatocellular carcinoma. Hepatology 1989, 9:457-460. 10.1002/hep.1840090320, 2537789.
4. Jonas S, Bechstein WO, Steinmuller T, Herrmann M, Radke C, Berg T, Settmacher U, Neuhaus P. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001, 33:1080-1086. 10.1053/jhep.2001.23561, 11343235.
5. Villa E, Moles A, Ferretti I, Buttafoco P, Grottola A, Del Buono M, De Santis M, Manenti F. Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology 2000, 32:233-238. 10.1053/jhep.2000.9603, 10915729.
6. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010, 30:61-74. 10.1055/s-0030-1247133, 20175034.
7. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954, 7:462-503. 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E, 13160935.
8. Miyata R, Tanimoto A, Wakabayashi G, Shimazu M, Nakatsuka S, Mukai M, Kitajima M. Accuracy of preoperative prediction of microinvasion of portal vein in hepatocellular carcinoma using superparamagnetic iron oxide-enhanced magnetic resonance imaging and computed tomography during hepatic angiography. J Gastroenterol 2006, 41:987-995. 10.1007/s00535-006-1890-2, 17096068.
9. Adachi E, Maeda T, Kajiyama K, Kinukawa N, Matsumata T, Sugimachi K, Tsuneyoshi M. Factors correlated with portal venous invasion by hepatocellular carcinoma: univariate and multivariate analyses of 232 resected cases without preoperative treatments. Cancer 1996, 77:2022-2031. 10.1002/(SICI)1097-0142(19960515)77:10<2022::AID-CNCR9>3.0.CO;2-S, 8640665.
10. Hagiwara S, Kudo M, Kawasaki T, Nagashima M, Minami Y, Chung H, Fukunaga T, Kitano M, Nakatani T. Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma. J Gastroenterol 2006, 41:1214-1219.
11. Terpos E, Szydlo R, Apperley JF, Hatjiharissi E, Politou M, Meletis J, Viniou N, Yataganas X, Goldman JM, Rahemtulla A. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003, 102:1064-1069. 10.1182/blood-2003-02-0380, 12689925.
12. Hefler LA, Concin N, Hofstetter G, Marth C, Mustea A, Sehouli J, Zeillinger R, Leipold H, Lass H, Grimm C, Tempfer CB, Reinthaller A. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res 2008, 14:710-714. 10.1158/1078-0432.CCR-07-1044, 18245530.
13. Nozoe T, Matsumata T, Kitamura M, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 1998, 176:335-338. 10.1016/S0002-9610(98)00204-9, 9817250.
14. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Aoki T, Sugaya M, Miyazawa Y, Hayashi H, Miyazaki S, Ochiai T. Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 2003, 83:248-252. 10.1002/jso.10275, 12884238.
15. Lin ZY, Wang LY, Yu ML, Chen SC, Chuang WL, Hsieh MY, Tsai JF, Chang WY. Role of serum C-reactive protein as a marker of hepatocellular carcinoma in patients with cirrhosis. J Gastroenterol Hepatol 2000, 15:417-421. 10.1046/j.1440-1746.2000.02149.x, 10824887.
16. Hashimoto K, Ikeda Y, Korenaga D, Tanoue K, Hamatake M, Kawasaki K, Yamaoka T, Iwatani Y, Akazawa K, Takenaka K. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 2005, 103:1856-1864. 10.1002/cncr.20976, 15779015.
17. Xavier P, Belo L, Beires J, Rebelo I, Martinez-de-Oliveira J, Lunet N, Barros H. Serum levels of VEGF and TNF-alpha and their association with C-reactive protein in patients with endometriosis. Arch Gynecol Obstet 2006, 273:227-231. 10.1007/s00404-005-0080-4, 16208475.
18. Fondevila C, Metges JP, Fuster J, Grau JJ, Palacin A, Castells A, Volant A, Pera M. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer 2004, 90:206-215. 10.1038/sj.bjc.6601455, 2395306, 14710231.
19. Chen XP, Qiu FZ, Wu ZD, Zhang ZW, Huang ZY, Chen YF, Zhang BX, He SQ, Zhang WG. Effects of location and extension of portal vein tumor thrombus on long-term outcomes of surgical treatment for hepatocellular carcinoma. Ann Surg Oncol 2006, 13:940-946. 10.1245/ASO.2006.08.007, 16788755.
20. Minagawa M, Makuuchi M, Takayama T, Kokudo N. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg 2003, 238:703-710. 10.1097/01.sla.0000094549.11754.e6, 1356149, 14578733.
21. Hong SS, Kim TK, Sung KB, Kim PN, Ha HK, Kim AY, Lee MG. Extrahepatic spread of hepatocellular carcinoma: a pictorial review. Eur Radiol 2003, 13:874-882.
22. Uchino K, Tateishi R, Shiina S, Kanda M, Masuzaki R, Kondo Y, Goto T, Omata M, Yoshida H, Koike K. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer 2011, 117:4475-4483. 10.1002/cncr.25960, 21437884.